PT  - JOURNAL ARTICLE
AU  - Skidmore, Peter T.
AU  - Kaelin, Emily A.
AU  - Holland, LaRinda A.
AU  - Maqsood, Rabia
AU  - Wu, Lily I.
AU  - Mellor, Nicholas J.
AU  - Blain, Joy M.
AU  - Harris, Valerie
AU  - LaBaer, Joshua
AU  - Murugan, Vel
AU  - Lim, Efrem S.
TI  - Emergence of a SARS-CoV-2 E484K variant of interest in Arizona
AID  - 10.1101/2021.03.26.21254367
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.26.21254367
4099  - http://medrxiv.org/content/early/2021/03/28/2021.03.26.21254367.short
4100  - http://medrxiv.org/content/early/2021/03/28/2021.03.26.21254367.full
AB  - SARS-CoV-2 is locked in a high-stakes arms race between the dynamics of rising population immunity and escape mutations. The E484K mutation in the spike protein reduces neutralization by post-vaccination sera and monoclonal antibody therapeutics. We detected the emergence of an E484K harboring variant B.1.243.1 from a common circulating variant (B.1.243) in the United States. In contrast to other instances when the E484K mutation was acquired independently in the parental lineage, genomic surveillance indicates that the B.1.243.1 variant of interest is in the process of being established in Arizona and beginning to cross state borders to New Mexico and Texas. Genomic, epidemiologic and phylogenetic evidence indicates that the B.1.243.1 variant of interest is poised to emerge. These findings demonstrate the critical need to continue tracking SARS-CoV-2 in real-time to inform public health strategies, diagnostics, medical countermeasures and vaccines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the Arizona State University Knowledge Enterprise and Arizona Department of Health Services.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Arizona State University Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data have been deposited in GISAID.